Holen Sie sich die Stockscreener-App
19.23
1.21%
0.23
Handel nachbörslich:
19.23
Avalo Therapeutics Inc Aktie (AVTX) Neueste Nachrichten
(AVTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Avalo Therapeutics Inc. (AVTX) Peer Comparison – Compare with Others - valueresearchonline.com
Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise (NASDAQ:AVTX) - Seeking Alpha
Avalo Therapeutics Inc. (AVTX) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Avalo Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com South Africa
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock - Investing.com
Avalo Therapeutics CFO Sullivan sells over $1.4m in stock By Investing.com - Investing.com Canada
Avalo Therapeutics (AVTX) CMO trades shares under 10b5-1 plan - Stock Titan
Avalo Therapeutics Inc. (AVTX) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
How Avalo Therapeutics Inc. (AVTX) Affects Rotational Strategy Timing - Stock Traders Daily
Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares By Investing.com - Investing.com Nigeria
Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares - Investing.com India
Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com Nigeria
Avalo Therapeutics CFO sells over $1.45 million in stock - Investing.com
AVTX | Avalo Therapeutics, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Avalo Therapeutics, Inc. Revenue Breakdown – NASDAQ:AVTX - tradingview.com
Deep Track Capital, LP Expands Avalo Therapeutics Inc (AVTX) Sta - GuruFocus
Avalo (AVTX) Q2 2026 Earnings: The EPS Result Is Below Expectation in the Latest Session; Post-Report: Shares Move 5.28% UpRevenue Growth Outlook - vinanet.vn
Avalo Therapeutics CMO Mittie Doyle Executes Stock Option and Sells 1,000 Shares Under 10b5-1 Plan - Kalkine Media
Avalo Therapeutics (AVTX) CMO sells 1,000 shares in plan - Stock Titan
Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing - marketscreener.com
Avalo Therapeutics (AVTX) CFO sells 72K shares in 10b5-1 trades - Stock Titan
Avalo (AVTX) Financial Update: Profit Per Share Falls Below Its Benchmark in Latest Trading; Post-Report - vinanet.vn
Avalo Therapeutics CFO Christopher Ryan Sullivan Executes Stock Options and Sells Shares Over Two Days - Kalkine Media
Avalo Therapeutics (NASDAQ: AVTX) insider lines up new stock sale after $74K August trade - Stock Titan
Avalo Therapeutics (AVTX) insider lines up $98.7K stock sale - Stock Titan
Avalo Therapeutics, Inc. SEC Filing (Aug 17, 2026) - Stock Titan
Avalo Therapeutics (NASDAQ: AVTX) insider to sell shares - Stock Titan
AVTX Q2 2026 Earnings: Wider-than-Expected Loss of -$0.83 Per Share Highlights Clinical-Stage BurnRevenue Growth Report - Vinanet
Wall Street Zen Upgrades Avalo Therapeutics (NASDAQ:AVTX) to Hold - marketbeat.com
Why Did AVTX Stock Surge 45% In Pre-Market Today? - Stocktwits
Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock By Investing.com - Investing.com Australia
Avalo Therapeutics CSO Jennifer Riley sells $52,012 in stock By Investing.com - Investing.com Canada
Avalo Therapeutics CSO Jennifer Riley sells $52,012 in stock - Investing.com
Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock - Investing.com
AVTX Surges Over 50% After Hours as Skin Disease Drug Shows Desired Clinical Results - Stocktwits
Avalo Therapeutics Stock Price Forecast. Should You Buy AVTX? - StockInvest.us
Avalo Therapeutics (AVTX): Nantahala Capital discloses 3.54% ownership stake - Stock Titan
Caligan Partners (NASDAQ: AVTX) reports 5.9% Avalo Therapeutics ownership on amended 13G - Stock Titan
RA Capital discloses 3.48M-share Avalo Therapeutics (AVTX) position in latest filing - Stock Titan
Avalo Therapeutics (AVTX): BVF group discloses 5.3% beneficial ownership stake - Stock Titan
Avalo Therapeutics (AVTX) sees T. Rowe Price report 3,670-share holding - Stock Titan
Avalo Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | C6K0 | US05338F3064 - marketscreener.com
Avoro Capital and Behzad Aghazadeh report 4.44% AVTX stake in 13G/A filing - Stock Titan
Deep Track Capital (AVTX) discloses 3.61M-share, 6.87% stake in Avalo - Stock Titan
Sei Investments Co. Invests $849,000 in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Avalo Therapeutics (AVTX) sees 5.5% stake reported by Affinity Asset Advisors and Michael Cho - Stock Titan
Avalo Therapeutics (AVTX) Chief Strategy Officer Jennifer Riley Sells 2,655 Shares - GuruFocus
Avalo Therapeutics (AVTX) CMO Mittie Doyle exercises options and sells 679 shares - Stock Titan
Avalo Therapeutics (AVTX) CSO Riley sells 2,655 shares at about $19.59 - Stock Titan
Avalo Therapeutics, Inc. $AVTX Shares Bought by Renaissance Technologies LLC - MarketBeat
Avalo Therapeutics (AVTX) insider plans NASDAQ resale of 2,655 ESPP shares - Stock Titan
Equities Analysts Issue Forecasts for AVTX Q3 Earnings - MarketBeat
Do Avalo Therapeutics’ (AVTX) Widening Losses But Better EPS Reveal a Turning Point in Strategy? - Yahoo Finance
Avalo Therapeutics (AVTX) insider schedules 679-share stock sale after option exercise - Stock Titan
Avalo Therapeutics (AVTX) Holds Near $18.29 as Shares Consolidate in a Narrow Trading BandSentiment Extreme - dars.gov.et
Avalo Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Bank of America Securities Reaffirms Their Buy Rating on Avalo Therapeutics (AVTX) - The Globe and Mail
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):